BlossomHill Therapeutics, Inc. (BLSM)
NASDAQ
Healthcare
Biotechnology
$14.51
▲ +0.69%
Market Cap
$422.0M
Sector
Healthcare
Industry
Biotechnology
Beta
0.00
52-Wk Range
11.02-27.99
CEO
Jing Rong Jean Cui
Country
US
Currency
USD
BlossomHill Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $14.51, up 0.69% on the session, giving a market capitalisation of $422.0M. On trailing twelve-month figures it carries a trailing P/E of -1.40, a net margin of 0.0%. Its beta of 0.00 implies it has historically moved less than the broad market.
Valuation & profitability (TTM)
P/E
-1.40
Price / Sales
0.00
Price / Book
1.87
EV / EBITDA
-3.05
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.11
Current ratio
12.82
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ
Employees
69
IPO date
2026-08-07
Headquarters
San Diego, CA, US
About BlossomHill Therapeutics, Inc.
Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.
Comparable companies
BlossomHill Therapeutics, Inc. is most often compared with the following Healthcare names:
More research on BLSM
Open full interactive analysis & DCF →